Targeson

Targeson is a biotechnology company specializing in the development of targeted ultrasound contrast agents and molecular imaging technologies. The company's core platform, Targestar, utilizes ligand-targeted microbubbles to enable high-resolution ultrasound imaging of specific molecular markers in vivo. These microbubbles are engineered to bind to biomarkers associated with angiogenesis, inflammation, and thrombosis, facilitating both diagnostic imaging and targeted drug or gene delivery. Primarily serving the preclinical research market, Targeson's products allow researchers to non-invasively monitor disease progression and therapeutic efficacy. In 2016, the company was acquired by FUJIFILM SonoSite, integrating its microbubble technology into a broader portfolio of ultrasound solutions.